1. Home
  2. WM vs SNY Comparison

WM vs SNY Comparison

Compare WM & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waste Management Inc.

WM

Waste Management Inc.

HOLD

Current Price

$238.44

Market Cap

92.9B

Sector

Utilities

ML Signal

HOLD

Logo Sanofi ADS

SNY

Sanofi ADS

HOLD

Current Price

$43.63

Market Cap

116.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WM
SNY
Founded
1968
1994
Country
United States
France
Employees
N/A
74846
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.9B
116.8B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
WM
SNY
Price
$238.44
$43.63
Analyst Decision
Buy
Buy
Analyst Count
20
6
Target Price
$253.95
$61.50
AVG Volume (30 Days)
2.2M
4.2M
Earning Date
04-29-2026
01-01-0001
Dividend Yield
1.58%
3.66%
EPS Growth
N/A
N/A
EPS
6.70
N/A
Revenue
$14,485,000,000.00
N/A
Revenue This Year
$8.26
$3.01
Revenue Next Year
$5.42
$5.80
P/E Ratio
$35.74
$6.14
Revenue Growth
6.44
N/A
52 Week Low
$194.11
$43.51
52 Week High
$248.13
$59.17

Technical Indicators

Market Signals
Indicator
WM
SNY
Relative Strength Index (RSI) 54.45 31.35
Support Level $213.90 N/A
Resistance Level $239.70 $48.97
Average True Range (ATR) 4.46 0.69
MACD -0.66 -0.35
Stochastic Oscillator 53.99 2.66

Price Performance

Historical Comparison
WM
SNY

About WM Waste Management Inc.

WM, previously known as Waste Management, ranks as the largest integrated provider of traditional solid waste services in the United States, operating 262 active landfill sites and about 339 transfer stations that help with transporting waste efficiently and economically. The company serves residential, commercial, industrial, and medical end markets for waste collection, transfer, and disposal. The company also has an energy business emanating from the beneficial use of landfill gas and is a leading recycler in North America.

About SNY Sanofi ADS

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Share on Social Networks: